CBIO CRESCENT BIOPHARMA, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1253689 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-58.7%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,216.6%
Net margin-727.6%
FCF margin-549.5%
EBITDA margin-1,214.9%
Returns
ROE-55.8%
ROA-49.9%
ROIC (approx.)—
Asset turnover0.07x
Leverage & solvency
Liabilities / assets8.4%
Debt / equity0.00x
Current ratio12.57x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-12.4%
Payout ratio—
Capex / revenue2.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.12M | $0 | $1.04M | $10.84M | $0 | $0 | $0 | $0 |
| R&D expense | $34.30M | $19.39M | $17.90M | $95.03M | $20.35M | $12.08M | $10.63M | $14.03M |
| SG&A expense | $8.72M | $8.74M | $7.87M | $7.31M | $5.54M | $8.95M | $3.60M | $3.16M |
| Operating income | -$39.91M | -$26.36M | -$24.73M | -$91.49M | -$25.89M | -$21.03M | -$14.22M | -$17.19M |
| Interest expense | $0 | $0 | $0 | $0 | $0 | $1.07M | $1.11M | $852,000 |
| Pretax income | — | — | — | — | — | — | — | -$17.87M |
| Income tax | $0 | $0 | $0 | $2.00M | $0 | $0 | $0 | $0 |
| Net income | -$37.73M | -$24.84M | -$23.28M | -$23.30M | -$24.61M | -$21.79M | -$15.15M | -$7.22M |
| EBITDA | -$39.84M | -$26.30M | -$24.66M | -$91.44M | -$25.86M | -$21.03M | -$14.22M | -$17.19M |
| EPS (basic) | — | — | — | — | — | — | -0.04 | — |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $289.36M | $171.59M | $189.16M | $213.19M | $133.26M | $152.65M | $22.43M | $34.77M |
| Receivables | $0 | $0 | $0 | $18.00M | — | — | — | $0 |
| Current assets | $295.21M | $179.01M | $195.56M | $236.66M | $134.56M | $154.23M | $5.99M | $34.80M |
| PP&E, net | $809,000 | $876,000 | $929,000 | $846,000 | $782,000 | $193,000 | — | $0 |
| Total assets | $299.50M | $182.76M | $199.13M | $240.29M | $138.27M | $157.43M | $5.99M | $35.62M |
| Current liabilities | $23.49M | $18.54M | $14.19M | $36.07M | $20.30M | $16.75M | $2.62M | $9.61M |
| Total liabilities | $25.22M | $19.50M | $15.28M | $37.28M | $21.63M | $18.18M | $2.62M | $47.10M |
| Shareholders' equity | $274.28M | $163.25M | $183.85M | $203.01M | $116.64M | $139.25M | -$30.16M | -$15.48M |
| Shares outstanding | 38.18M | 27.76M | 27.57M | 27.56M | 13.89M | 13.89M | 64.53M | 1.02M |
| Cash flow statement | ||||||||
| Operating cash flow | -$26.94M | -$19.46M | -$8.94M | -$26.74M | -$17.54M | -$22.15M | -$10.85M | -$6.27M |
| Capital expenditure | $0 | $13,000 | $147,000 | $193,000 | $586,000 | $140,000 | $0 | $0 |
| Free cash flow | -$26.94M | -$19.48M | -$9.08M | -$26.93M | -$18.12M | -$22.29M | -$10.85M | -$6.27M |
| Investing cash flow | $0 | $1.76M | -$8.15M | -$72.19M | -$586,000 | -$140,000 | $0 | $0 |
| Financing cash flow | $144.81M | $136,000 | -$6.95M | $178.86M | -$1.25M | $146.86M | -$1.49M | $41.03M |
| Depreciation & amortization | $67,000 | $66,000 | $64,000 | $54,000 | $28,000 | $2,000 | $0 | $0 |
| Stock-based compensation | $4.22M | $3.96M | $4.11M | $4.75M | $1.99M | $5.34M | $1.23M | $1.13M |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.